Scholarlink

<p>We conducted a prospective cohort study to assess IPV experiences after returning recency test results to PLHIV in Rwanda. At 60 health facilities, newly diagnosed PLHIV underwent HIV recency testing and baseline viral load measurement. Recency test results were returned after viral load testing. During interviews conducted at four study visits over 6 months, participants self-reported IPV victimization and perpetration experiences with current partner(s) in the past four weeks. We compared IPV prevalence before/after HIV diagnosis and before/after return of recency test results. Victimization experiences were also compared between recent (RT) and long-term (LT) cases using generalized linear mixed models. Between August 2021 and October 2022, 932 newly diagnosed PLHIV had IPV data from ≥ 1 visits after return of recency test results. Of these, 91.1% had LT infection and 8.9% had RT infection. Victimization prevalence was higher before HIV diagnosis compared to after HIV diagnosis (29.8% vs. 17.6%, <i>p</i> &lt; 0.001) and did not increase after return of recency test results at 2 (17.6% vs. 16.8%, <i>p</i> = 0.7) or 6 months (17.6% vs. 15.3%, <i>p</i> = 0.2). Victimization or perpetration prevalence did not differ between RT and LT participants before/after return of recency test results, and return of RT infection result was not associated with increased victimization relative to return of LT infection result in multivariable analysis. In a setting with high baseline IPV, returning recency test results did not increase IPV experience over 6 months. HIV testing services should nonetheless continue to implement strategies to mitigate IPV risks.</p><p><?noindent??>Clinical Trial Number: NCT05063487.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Self-reported Intimate Partner Violence Before and After Return of Recency Test Results: Findings from the Rwanda HIV Recency Evaluation Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Eugenie Poirot,
  • Giles Reid,
  • Suzue Saito,
  • Jean Claude Irabona,
  • Collins Kamanzi,
  • Vusumuzi Maliwa,
  • Veronicah Mugisha,
  • Eric Remera,
  • Beata Sangwayire,
  • Eugenie Kayirangwa,
  • Samuel Malamba,
  • Meagan Cain,
  • Jennifer Hegle,
  • Jessica Justman,
  • Stephanie Behel,
  • Gallican N. Rwibasira,
  • Vedaste Masengesho,
  • Jarjieh Fang,
  • Koen Frederix,
  • Tom Oluoch,
  • Richard Mwesigwa,
  • Elysee Tuyishime,
  • Jared Omolo,
  • Gentille Musengimana,
  • Bharat Parekh,
  • Monita Patel,
  • David Miller,
  • Amitabh Suthar,
  • Kemba Lee

摘要

We conducted a prospective cohort study to assess IPV experiences after returning recency test results to PLHIV in Rwanda. At 60 health facilities, newly diagnosed PLHIV underwent HIV recency testing and baseline viral load measurement. Recency test results were returned after viral load testing. During interviews conducted at four study visits over 6 months, participants self-reported IPV victimization and perpetration experiences with current partner(s) in the past four weeks. We compared IPV prevalence before/after HIV diagnosis and before/after return of recency test results. Victimization experiences were also compared between recent (RT) and long-term (LT) cases using generalized linear mixed models. Between August 2021 and October 2022, 932 newly diagnosed PLHIV had IPV data from ≥ 1 visits after return of recency test results. Of these, 91.1% had LT infection and 8.9% had RT infection. Victimization prevalence was higher before HIV diagnosis compared to after HIV diagnosis (29.8% vs. 17.6%, p < 0.001) and did not increase after return of recency test results at 2 (17.6% vs. 16.8%, p = 0.7) or 6 months (17.6% vs. 15.3%, p = 0.2). Victimization or perpetration prevalence did not differ between RT and LT participants before/after return of recency test results, and return of RT infection result was not associated with increased victimization relative to return of LT infection result in multivariable analysis. In a setting with high baseline IPV, returning recency test results did not increase IPV experience over 6 months. HIV testing services should nonetheless continue to implement strategies to mitigate IPV risks.

Clinical Trial Number: NCT05063487.